Protagenic Therapeutics, Inc.\new 8-K
Research Summary
AI-generated summary
Protagenic Therapeutics, Inc. CFO Departing Effective April 30, 2026
What Happened
Protagenic Therapeutics, Inc. filed a Form 8-K (Item 5.02) on April 7, 2026 reporting that the Board notified Chief Financial Officer Alexander Arrow, M.D., on March 31, 2026 that his employment will be terminated effective April 30, 2026. The 8-K discloses the departure but does not provide reasons or identify a successor.
Key Details
- Board notification date: March 31, 2026.
- Termination effective date: April 30, 2026.
- Officer affected: Alexander Arrow, M.D., Chief Financial Officer.
- Filing: Form 8-K submitted April 7, 2026; the filing does not disclose any termination agreement, severance terms, or replacement.
Why It Matters
A CFO departure is a material executive change that can affect financial reporting continuity and investor confidence. Because the filing provides no details on replacement or severance, investors should watch for follow-up SEC filings (additional 8-Ks or press releases) that disclose an interim or new CFO and any related agreements or impacts on financial controls.